Bristol cuts its BCMA losses
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
